| Drug Name |
Alogliptin |
| Drug ID |
BADD_D00079 |
| Description |
Alogliptin is a selective, orally-bioavailable inhibitor of enzymatic activity of dipeptidyl peptidase-4 (DPP-4). Chemically, alogliptin is prepared as a benzoate salt and exists predominantly as the R-enantiomer (>99%). It undergoes little or no chiral conversion in vivo to the (S)-enantiomer. FDA approved January 25, 2013. |
| Indications and Usage |
Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. |
| Marketing Status |
approved |
| ATC Code |
A10BH04 |
| DrugBank ID |
DB06203
|
| KEGG ID |
D06553
|
| MeSH ID |
C520853
|
| PubChem ID |
11450633
|
| TTD Drug ID |
D0NJ5H
|
| NDC Product Code |
64764-250; 45802-087; 66332-7001; 66332-7003; 45802-103; 11532-7001; 71610-300; 64764-125; 64764-625; 11532-7002; 45802-150; 71610-661; 65392-2813; 50090-5574; 66332-7002; 11532-7003 |
| UNII |
JHC049LO86
|
| Synonyms |
alogliptin | 2-((6-((3R)-3-aminopiperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl) benzonitrile | nesina | SYR 322 | SYR322 | SYR-322 |
